TY - JOUR
T1 - Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors
T2 - a single-surgeon experience
AU - Supron, Andrew D.
AU - Cheaib, Joseph G.
AU - Biles, Michael J.
AU - Schwen, Zeyad
AU - Allaf, Mohamad
AU - Pierorazio, Phillip M.
N1 - Publisher Copyright:
© 2020, Springer-Verlag London Ltd., part of Springer Nature.
PY - 2021/4
Y1 - 2021/4
N2 - The objectives were to evaluate the safety and oncologic efficacy of primary robotic retroperitoneal lymph node (R-RPLND) dissection for testicular germ cell tumors. A retrospective analysis was performed on all primary R-RPLND cases performed by a single surgeon, who performs both open and R-RPLND at a high-volume academic institution, between August 2013 and August 2019. Data on patient demographics, operative techniques, perioperative outcomes, and tumor characteristics were obtained. 28 men were identified who underwent primary R-RPLND. The majority of patients (N = 21, 75%) had clinical stage I disease, and a bilateral template was more commonly performed than either single side alone (N = 13, 46%). Of note, two cases involving clinical stage II disease were converted electively from robotic to open procedures at the discretion of the surgeon. R-RPLND patients experienced no intraoperative complications. The median follow-up time was 8 months (interquartile range 4–29 months). One (4%) patient developed a disease recurrence at 10 months after R-RPLND. Conclusion: primary R-RPLND is a safe and efficacious procedure for carefully selected men with stage I and II non-seminomatous germ cell tumors of the testis. Long-term data are needed to evaluate the comparative oncologic efficacy with open surgery and the notably high rate of chylous ascites.
AB - The objectives were to evaluate the safety and oncologic efficacy of primary robotic retroperitoneal lymph node (R-RPLND) dissection for testicular germ cell tumors. A retrospective analysis was performed on all primary R-RPLND cases performed by a single surgeon, who performs both open and R-RPLND at a high-volume academic institution, between August 2013 and August 2019. Data on patient demographics, operative techniques, perioperative outcomes, and tumor characteristics were obtained. 28 men were identified who underwent primary R-RPLND. The majority of patients (N = 21, 75%) had clinical stage I disease, and a bilateral template was more commonly performed than either single side alone (N = 13, 46%). Of note, two cases involving clinical stage II disease were converted electively from robotic to open procedures at the discretion of the surgeon. R-RPLND patients experienced no intraoperative complications. The median follow-up time was 8 months (interquartile range 4–29 months). One (4%) patient developed a disease recurrence at 10 months after R-RPLND. Conclusion: primary R-RPLND is a safe and efficacious procedure for carefully selected men with stage I and II non-seminomatous germ cell tumors of the testis. Long-term data are needed to evaluate the comparative oncologic efficacy with open surgery and the notably high rate of chylous ascites.
KW - Retroperitoneal lymph node dissection
KW - Robotic urology
KW - Testicular cancer
KW - Urology
UR - http://www.scopus.com/inward/record.url?scp=85086781542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086781542&partnerID=8YFLogxK
U2 - 10.1007/s11701-020-01107-1
DO - 10.1007/s11701-020-01107-1
M3 - Article
C2 - 32572754
AN - SCOPUS:85086781542
SN - 1863-2483
VL - 15
SP - 309
EP - 313
JO - Journal of Robotic Surgery
JF - Journal of Robotic Surgery
IS - 2
ER -